Peritoneal Neoplasms clinical trials
The registry lists 249 studies for Peritoneal Neoplasms across more than 10 countries. 55 are recruiting or about to start. 113 of them are mainly about Peritoneal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Peritoneal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (13) · Hospices Civils de Lyon (9) · University Hospital, Ghent (7) · M.D. Anderson Cancer Center (6) · Jules Bordet Institute (5) · Institut du Cancer de Montpellier - Val d'Aurelle (5) · Eli Lilly and Company (5) · Hoffmann-La Roche (4)
What is being tested here
Drugs under test in Peritoneal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Oxaliplatin | 4 | 1 | 8 |
| Mitomycin | 4 | 0 | 6 |
| Cisplatin | 3 | 0 | 13 |
| Fluorouracil | 3 | 0 | 7 |
| Paclitaxel | 2 | 2 | 18 |
| Bevacizumab | 2 | 1 | 5 |
| Doxorubicin | 2 | 0 | 3 |
| Sodium thiosulfate | 1 | 0 | 3 |
| Docetaxel | 1 | 0 | 3 |
| Irinotecan | 1 | 0 | 2 |
Drug classes tested here Alkylating agents 5 open · Antimitotic agents 3 open · Antimetabolites 3 open · Angiogenesis inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 6
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery · Phase 3 · CanariaBio Inc.
- Jul 2027MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) · Phase 3 · Swiss GO Trial Group
- Nov 2026PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis · University of California, Irvine
- Dec 2026Galunisertib Combined With Capecitabine in Advanced CRC With PM · The Netherlands Cancer Institute
- Dec 2026Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma · Columbia University
- Dec 2026Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis · University of California, Irvine
- Dec 2026Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis · University of California, Irvine
- Dec 2026Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis · Institut du Cancer de Montpellier - Val d'Aurelle
- Dec 2026Preventive Use of PIPAC in Locally Advanced Gastric Cancer. · National Research Oncology and Transplantology Center, Kazakhstan
- Jul 2027Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers · Institut du Cancer de Montpellier - Val d'Aurelle
Who these studies take
Of the 49 Peritoneal Neoplasms studies recruiting now, 35 (71%) set no upper age limit and 8 (16%) stop at 75 or younger. 3 (6%) take children under 18. 8 (16%) are for women only and 0 (0%) for men only; 2 (4%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (6%) | 2 (4%) |
| 18 | 46 (94%) | 38 (78%) |
| 30 | 49 (100%) | 41 (84%) |
| 40 | 49 (100%) | 41 (84%) |
| 50 | 49 (100%) | 41 (84%) |
| 65 | 49 (100%) | 41 (84%) |
| 75 | 47 (96%) | 39 (80%) |
| 85 | 38 (78%) | 33 (67%) |
Across all 249 studies, recruiting or not: 17% stop at 75 or younger and 3% at 65; 8% take children; 27% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Peritoneal Neoplasms studies take
Of 28 phase 2 interventional studies under Peritoneal Neoplasms, half reached primary completion within 62 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 70 mo39–105 · 27 studies | — | — |
| Phase 2 | 62 mo28–96 · 28 studies | — | — |
| Interventional, no phase | 30 mo19–80 · 34 studies | — | — |
| Observational | 71 mo23–… · 23 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Stopped1
- AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian CancerTerminatedOct 29, 2026NCT05617755
Studies
Recruiting first, then most recently updated. Showing 50 of 249. Browse all 249 → or search them.
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingNCT04847063Phase 11 country
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingNCT06787612Phase 25 countries
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 327 countries
- Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal CarcinomatosisRecruitingNCT07030283Phase 11 country
- Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal CarcinomatosisRecruitingNCT07475286Phase 21 country
- A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal MesotheliomaRecruitingNCT06623396Phase 11 country
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian CancerRecruitingNCT04811703Phase 11 country
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityRecruitingNCT07001748Phase 2/31 country
- Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal CancerNot yet recruitingNCT07856914Phase 2
- TLR9 Immunotherapy for Peritoneal CarcinomatosisRecruitingNCT07658196Phase 11 country
- Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal ChemotherapyRecruitingNCT06351475Not applicable1 country
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid TumorsRecruitingNCT07487168Phase 11 country
- Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric CancerRecruitingNCT04107077Phase 21 country
- Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was PerformedRecruitingNCT016173821 country
- Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal CancerRecruitingNCT056523481 country
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingNCT04329494Phase 11 country
- Remimazolam Versus Propofol for Early Recovery After Cytoreductive SurgeryNot yet recruitingNCT07785557Not applicable1 country
- The Appendix Cancer PMP Research Foundation Natural History Study/Patient RegistryRecruitingNCT077693461 country
- Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal CarcinomatosisRecruitingNCT05844865Not applicable1 country
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 28 countries
- Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel ObstructionRecruitingNCT04840264Phase 21 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)RecruitingNCT07219238Phase 2/32 countries
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking SurgeryRecruitingNCT06504147Phase 26 countries
- MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).Not yet recruitingNCT07593261Phase 21 country
- Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)RecruitingNCT05913674Phase 21 country
- Intensification Treatment of Ovarian Cancer by PIPACRecruitingNCT07514494Phase 21 country
- Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)RecruitingNCT07493876Not applicable1 country
- Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPECRecruitingNCT04779554Phase 21 country
- To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.RecruitingNCT07493421Not applicable2 countries
- Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.RecruitingNCT074514831 country
- Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)RecruitingNCT07282834Phase 21 country
- PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal CarcinomatosisRecruitingNCT06511037Early Phase 11 country
- Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.RecruitingNCT06929013Not applicable1 country
- Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal CarcinosisRecruitingNCT04024917Not applicable1 country
- Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian CancerNot yet recruitingNCT07273396Phase 1/2
- MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)RecruitingNCT04111978Phase 33 countries
- Prophylactic PIPAC in Patients With High-risk Colorectal CancerNot yet recruitingNCT06839092Phase 3
- Preventive Use of PIPAC in Locally Advanced Gastric Cancer.RecruitingNCT06784765Not applicable1 country
- Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal CarcinomatosisRecruitingNCT06061874Not applicable1 country
- Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal CancersRecruitingNCT03976999Not applicable1 country
- Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)RecruitingNCT05250648Phase 41 country
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal CarcinomatosisRecruitingNCT05395910Phase 11 country
- Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal CarcinomatosisRecruitingNCT04547725Not applicable1 country
- Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal MetastasesRecruitingNCT05371223Phase 21 country
- SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive SurgeryRecruitingNCT062237631 country
- Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal CarcinomatosisRecruitingNCT03073694Phase 21 country
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian CancerRecruitingNCT05801783Early Phase 11 country
- Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer PatientsRecruitingNCT03280511Phase 21 country
- Longitudinal Study of CRS/HIPEC for Peritoneal CarcinomatosesRecruitingNCT041089361 country